Aduro BioTech Inc (NASDAQ:ADRO) insider Stephen T. Isaacs sold 40,000 shares of Aduro BioTech stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $9.38, for a total value of $375,200.00. Following the completion of the transaction, the insider now owns 213,921 shares in the company, valued at $2,006,578.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of Aduro BioTech Inc (ADRO) opened at $8.20 on Thursday. Aduro BioTech Inc has a 1-year low of $6.01 and a 1-year high of $14.05.
Aduro BioTech (NASDAQ:ADRO) last announced its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.03). The business had revenue of $3.79 million during the quarter, compared to analyst estimates of $4.04 million. Aduro BioTech had a negative return on equity of 39.28% and a negative net margin of 548.92%. The firm’s revenue was up .0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.54) earnings per share. equities research analysts forecast that Aduro BioTech Inc will post -1.28 EPS for the current year.
A number of equities research analysts recently weighed in on the company. Oppenheimer assumed coverage on Aduro BioTech in a research report on Monday, October 30th. They set a “buy” rating and a $15.00 target price on the stock. HC Wainwright set a $18.00 target price on Aduro BioTech and gave the stock a “buy” rating in a research report on Tuesday, October 17th. Finally, William Blair reissued an “outperform” rating on shares of Aduro BioTech in a research report on Monday, October 2nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company’s stock. Aduro BioTech has an average rating of “Buy” and an average target price of $19.14.
About Aduro BioTech
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
What are top analysts saying about Aduro BioTech Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aduro BioTech Inc and related companies.